Globus Medical (NYSE:GMED) announced today that it agreed to acquire chronic pain treatment developer Nevro (NYSE:NVRO).

Analysts said Nevro’s valuation was “inexpensive,” but the spinal cord stimulation business can benefit from Globus’ scale ...

Jan. 22, 2015 /PRNewswire/ -- Nevro Corp. (NYSE ... of its Premarket Approval Application (PMA) for the Senza spinal cord stimulation (SCS) system. According to the approvable letter, approval ...

Nevro Corp. NVRO recently received CE Mark Certification in Europe for its HFX iQ spinal cord stimulation (SCS) system. The company can now market HFX iQ in all countries that recognize this ...

Nevro NVRO is well-poised for growth in ... However, concerns regarding softness in the spinal cord stimulation (SCS) market and dependence on third-party payers persist. This Zacks Rank #2 ...